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Introduction
Lower limb peripheral artery disease (PAD) is a 
common comorbidity in patients with diabetes 
mellitus (DM) and chronic kidney disease 
(CKD).1–3 Atherosclerotic disease pattern in 
PAD is influenced by cardiovascular risk fac-
tors.4,5 CKD and DM are known to be the lead-
ing cause for vascular calcification and share 
similar pathomorphological aspects.6 DM was 
shown to be a significant predictor for below the 
knee (BTK) artery involvement5 and small vessel 
disease defined as the highest 10% of toe brachial 
index decline with limited ankle brachial index.4 
Major cardiovascular disease trials frequently 
exclude patients with CKD and do not provide 
adequate information on renal function of enroll-
ees or effect of interventions on patients with 
CKD without DM.7
DM and CKD are associated with critical limb 
ischemia (CLI)8–10 that goes along with a high 
rate of minor and major amputations.11,12 The 
importance of patency of the pedal–plantar arch 
on the rate of amputations was suggested in early 
series derived from patients with DM13 or end 
stage renal disease (ESRD).14 It is rather more 
recently that patency of the pedal–plantar arch as 
well as obstructive burden of pedal arteries has 
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become a dedicated focus of interest for the 
understanding of poor clinical limb outcome after 
distal bypass or endovascular treatment.3,15–19
Kidney disease is a frequent complication in 
DM.20 Differentiation between DM and CKD as 
leading risk factors for marked distal atheroscle-
rotic disease pattern in studies of PAD is missing, 
and in patients with CKD, it is mainly limited to 
patients with ESRD.2,3,16,21,22
In this retrospective, single-center PAD patient 
group analysis, patency of the arterial pedal–
plantar arch and occlusion of BTK arteries 
were assessed with respect to the coexistence of 
DM or CKD. The hypothesis was that loss of 
patency of the pedal–plantar arch is more fre-
quent in patients with CKD compared with 
patients without CKD, independent of the 
presence of DM.
Patients and methods
Study design
For a retrospective analysis, patients were selected 
from a consecutive, prospectively collected, cross-
sectional database of patients undergoing digital 
subtraction angiography (DSA) for symptomatic 
PAD. The time span was from January 2010 to June 
2015 for the patient’s first visit to the Swiss 
Cardiovascular Center, Division of Vascular 
Medicine at Bern University Hospital, Switzerland, 
a tertiary referral center responsible for peripheral 
vascular service in a population of about one million 
subjects. Noninvasive Doppler examination and 
duplex scan are routine first-line assessments fol-
lowed by DSA if an indication for revascularization 
is given. It can be assumed that <5% of sympto-
matic patients referred were excluded from analysis 
because of an other-than-angiographic assessment 
(Figure 1). Patients with DM and CKD were 
Figure 1. Flow chart of patient enrollment.
CKD, chronic kidney disease; GFR, glomerular filtration rate; DM, diabetes mellitus; PAD, peripheral artery disease.
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consecutively selected, the PAD-control group was 
randomly selected to match in number of patients 
included. Selection of patients was regardless of their 
clinical status of PAD and was undertaken in a two-
step procedure. In a first step, patients had to have a 
known and determined status of cardiovascular risk 
factors. In a second step, DSA had to have adequate 
readability of the pedal–plantar artery arch as quoted 
by two independent reviewers. With focus on assess-
ing whether there is an independent influence of 
CKD as compared with DM on patency of the 
pedal–plantar arch, inclusion criterion was sympto-
matic PAD to prevent selection bias, for example, 
patients with predominant BTK disease often seen 
in CLI. Inclusion criteria were: patients aged > 18 
years with symptomatic chronic PAD as defined 
according to international guidelines,23,24 ankle– 
brachial index < 0.9 or toe–brachial index < 0.6, 
undergoing DSA without previous revascularization, 
and readable DSA for analysis of the atherosclerotic 
burden of the lower limb and pedal arteries. 
Exclusion criteria were low-quality DSA not suitable 
for analysis of atherosclerotic burden, that is, 
unknown inflow, low-contrast filling, inadequate 
pedal arch documentation, nonatherosclerotic dis-
ease, acute limb ischemia, or previous revasculariza-
tion. Overall, 419 patients met the inclusion criteria. 
Patients were stratified according to the following 
prespecified groups: patients without DM and with-
out CKD (PAD-control, n = 149), patients with 
DM without CKD (DM, n = 183). Patients 
with CKD without DM (CKD, n = 87). The 
research protocol was approved by the institutional 
review board of cantonal ethic committee according 
to the guideline of the 1975 Declaration of Helsinki 
and its amendments. As this was a retrospective 
study, the need to obtain written informed consent 
was waived and patients’ records were anonymized 
before analysis.
Angiographic scoring
DSAs were read in a random order by two 
experienced readers. Both readers were 
blinded to clinical data, especially blinded to 
the groups. Patency of the pedal–plantar arch 
was defined according to the definition of 
Higashimori and colleagues17 with arterial 
flow through either lateral branch of the plan-
tar–pedal artery or dorsal–pedal artery reach-
ing the opposite artery through connection via 
the deep penetrating artery (Figure 2). A con-
sensus had to be found regarding patency of 
the pedal–plantar loop.
Figure 2. Interrupted dorsal–pedal artery (1), interrupted lateral branch of plantar–pedal artery (2) and 
interrupted pedal–plantar arch (3) (A); communicating dorsal–pedal artery with open lateral-branch plantar 
of the plantar–pedal artery with a patent pedal–plantar arch (B).
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Definition of risk factors and comorbidity
Presence of DM was defined by glycosylated 
hemoglobin > 6.5% or if the patient was on insulin 
therapy or oral antidiabetics.25 CKD patients were 
identified by calculation of the estimated glomeru-
lar filtration rate (eGFR) using the Modification of 
Diet in Renal Disease (MDRD) formula < 60 ml/
min.26 CKD was classified according to severity of 
renal failure as moderate CKD with an eGFR of 
30–59 ml/min and severe CKD with an eGFR < 
29 ml/min. ESRD was defined as GFR < 15 ml/
min or on dialysis.27 Arterial hypertension was 
defined by systolic blood pressure > 140 mmHg or 
diastolic blood pressure > 80 mmHg, or if any 
antihypertensive drug was consumed. 
Hyperlipidemia was defined by total cholesterol 
level > 5 mmol/l, or triglycerides > 2 mmol/l or 
high-density lipoprotein cholesterol < 1 mmol/l, or 
if any lipid-lowering drug was consumed. Patients 
were classified as ever-active smokers or nonsmok-
ers, according to records.
Statistics
Descriptive analyses of sociodemographic charac-
teristics were based on patient characteristics at the 
time of the performed angiogram. Demographic 
and clinical characteristics of the study population 
are reported as mean [±standard deviation (SD)] 
for continuous variables and as number (percent-
age) for categorical variables.
Binary outcomes were analyzed using logistic 
regression and presented as odds ratios (OR) and 
95% confidence intervals (CI). p values are from 
Wald tests. Discrete outcomes with three or more 
levels were analyzed using χ2 tests. Where indi-
cated, models were adjusted for age, sex, hyperten-
sion, hyperlipidemia and smoking status. Interrater 
reliability was measured by kappa coefficient for 
nominal categorical variable (occlusion of tibial and 
peroneal arteries or loss of patency of pedal–plantar 
arch). Intrarater reliability was not evaluated. 
Statistical analyses were performed using Stata 
14.2 (StataCorp. 2015. Stata Statistical Software: 
Release 14. College Station, TX: StataCorp LP.).
Results
Baseline characteristics
Overall 419 patients fulfilling inclusion criteria 
and were analyzed for pedal–plantar arch 
patency and atherosclerotic occlusion of BTK 
arteries. The three groups differed statistically 
significant in patient number, mean age and 
active smoking status. Demographic data are 
shown in Table 1.
Loss of patency of the pedal–plantar loop
The adjusted ORs for loss of patency of pedal–
plantar loop were higher in CKD above both 
PAD-control [OR 1.39 (95% CI 0.67–2.87), p = 
0.37], diabetics [OR 1.32 (95% CI 0.64–2.72), 
p = 0.46] and both [OR 1.35 (95% CI 0.69–
2.64), p = 0.38]. DM did not show a higher OR 
above PAD-control [OR 1.05 (0.61–1.83), p = 
0.85]. However, the ORs were not statistically 
significant (Table 2).
Within the subgroup of CKD, patients’ loss of 
patency of the pedal loop was related to the sever-
ity of CKD. Moderate CKD (eGFR 30–59 ml/
min) did not show higher ORs after controlling 
for age, sex, hypercholesterolemia, arterial hyper-
tension and smoking [OR 0.93 (95% CI 0.43–
2.01), p = 0.85]. Instead, patients with severe 
CKD (eGFR ≤29 ml/min) showed significantly 
increased adjusted ORs compared with patients 
with normal kidney function, even after adjust-
ment for baseline factors [OR 8.24 (95% CI 
0.99–68.36), p = 0.05; Table 3].
Burden of atherosclerotic disease in  
below-the-knee arteries
CKD was not related to the risk of tibial or pero-
neal artery occlusion, whereas the risk of an 
occlusion of at least one BTK artery was 2.5-fold 
increased in patients with DM as compared with 
PAD-controls and CKD patients. The adjusted 
OR for occlusion of BTK arteries in PAD-control 
versus CKD was 1.09 (95% CI 0.49–2.44, p = 
0.83), PAD-control versus DM was 2.41 (95% CI 
1.23–4.72, p = 0.01), and CKD versus DM 2.21 
(95% CI 0.93–5.22, p = 0.07), respectively.
Consistency of our interrater agreement was good 
to very good for rating on occlusion of tibial and 
peroneal arteries and moderate for rating on loss of 
patency of the pedal–plantar arch (Supplementary 
Table 1). As there was lowest interrater agreement 
within the subgroup of CKD, data shown refer to a 
consensus between two raters. For those patients 
without agreement with loss of patency of the pedal–
plantar arch, a consensus between the two readers 
was found. Analysis showed comparable results if 
CKD was defined as plasma creatinine level > 105 
µmol/l as compared with eGFR < 60 ml/min.
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Discussion
Focus of this first evaluation of the pedal–plantar 
arch in patients with PAD was to study whether 
there is an independent influence of CKD and 
DM on patency. Severe CKD with an eGFR less 
than 29 ml/min seems to be an important vascular 
Table 1. Demographic data on 419 patients enrolled into the study.
Total group PAD-control DM CKD p value
 n = 419 n = 149 n = 183 n = 87
Age, years ± SD  75.2 ± 10.3 75.2 ± 9.9 73.4 ± 9.8  79.0 ± 11.1 <0.001
Male, n (%) 288 (69) 103 (69) 124 (68) 61 (70) 0.919
Serum creatinine mean ± 
SD (µmol/l)
100.6 ± 86.2 75.0 ± 15.5 75.5 ± 15.1 197.4 ± 152.7 <0.001
eGFR mean ± SD (ml/min)  79.4 ± 30.5 90.3 ± 23.5 89.9 ± 24.0  38.6 ± 15.5 <0.001
Severe (<29 ml/min) 23 (5%) 0 (0%) 0 (0%) 23 (26%) <0.001
Moderate (30–59 ml/min) 64 (15%) 0 (0%) 0 (0%) 64 (74%) <0.001
Normal (⩾60 ml/min) 332 (79%) 149 (100%) 183 (100%) 0 (0%) <0.001
Hyperlipidemia 0.661
Yes 242 (58%) 88 (59%) 100 (55%) 54 (62%) 0.474
No 115 (27%) 42 (28%) 51 (28%) 22 (25%) 0.878
Unknown 62 (15%) 19 (13%) 32 (17%) 11 (13%) 0.394
Hypertension 0.610
Yes 372 (89%) 130 (87%) 163 (89%) 79 (91%) 0.696
No 41 (10%) 17 (11%) 16 (9%) 8 (9%) 0.703
Unknown 6 (1%) 2 (1%) 4 (2%) 0 (0%) 0.366
Active smoking 0.011
Yes 178 (42%) 78 (52%) 70 (38%) 30 (34%) 0.008
No 180 (43%) 59 (40%) 81 (44%) 40 (46%) 0.566
Unknown 61 (15%) 12 (8%) 32 (17%) 17 (20%) 0.018
Tests for continuous variables are ANOVAs, 2 tests were used for categorical variables.
CKD, chronic kidney disease; DM, diabetes; PAD-control, peripheral artery disease with neither diabetes nor chronic kidney disease; SD, standard 
deviation; eGFR, estimated glomerular filtration rate.
Table 2. Loss of patency of the pedal–plantar arch.
n/n Adjusted OR 
(95% CI)
Adjusted*  
p-value
Adjusted OR* 
(95% CI)
PAD-control versus CKD 149/87 1.39 (0.67–2.87) 0.37
patency loss of patency
PAD-control versus DM 149/183 1.05 (0.61–1.83) 0.85
PAD-control/DM versus CKD 332/87 1.35 (0.69–2.64) 0.38
DM versus CKD 183/87 1.32 (0.64–2.72) 0.46
*Adjusted models included age, sex, hypercholesterolemia, arterial hypertension and smoking.
CKD, chronic kidney disease; DM, diabetes; PAD, peripheral artery disease; OR, odds ratio; CI, confidence interval.
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risk factor for loss of patency of the pedal-plantar 
arch in patients with symptomatic PAD. 
Moreover, analysis shows that BTK vascular dis-
ease pattern differs in patients with either DM or 
CKD alone. Patients with DM seem to have pro-
nounced occlusive disease of tibial and peroneal 
arteries, whereas patients with severe CKD have 
pronounced pedal artery disease.
Studies on PAD patients providing data on 
patency of pedal arteries including the pedal arch 
are rare and include a limited number of patie-
nts.2,13,16,17,28–30 Various risk factors influence the 
pattern of lower limb atherosclerosis in PAD 
patients, with DM and CKD typically associated 
with pronounced distal disease4,5 and vascular 
calcification.6 Comparative data on the disease 
patterns in pedal and BTK arteries with strict dif-
ferentiation of patients with PAD suffering from 
either DM or CKD are missing.
There is growing evidence showing that even 
moderate renal insufficiency is associated with 
arterial calcification,31–33 and that coronary 
artery calcification, its progression and impact 
on a rise in cardiovascular events is associated 
with CKD at predialysis status.34,35 Thereby, 
progression rate of CAC among patients with 
ESRD is higher compared with diabetes patients 
without and also with a predialysis status.36 In 
accordance, loss of kidney function is also asso-
ciated with an increase of calcification in PAD.22 
Furthermore, it is described that a decrease in 
GFR level by 10 ml/min per 1.73 m2 is associ-
ated with a relative risk ratio of 1.08 for the pres-
ence of distal limb artery disease involvement 
with ESRD as an independent predictor for a 
centrifugal arterial lesion pattern (relative risk 
ratio 7.72, 95% CI 3.0–19.88, p < 0.0001).37 
Data presented that severe CKD is associated 
with pedal arch occlusion are well in accordance 
with these findings.
Data on the atherosclerotic disease pattern in 
PAD with a distinction of diabetes and CKD are 
scarce. In a small-sized group of patients with 
critical limb ischemia (CKD group n = 15, DM 
group = 25), Diehm and colleagues have shown 
that patency rate of at least one pedal artery is 
72% in patients with DM compared with 47% in 
patients with CKD and 48% for patients suffering 
from both CKD and DM.2 In another analysis 
from Brosi and colleagues, a complete occlusion 
of both the plantar–pedal arch and dorsal–pedal 
arch was found in 58% in those PAD patients 
with ESRD.21 Kawarada and colleagues analyzed 
three different types of pedal-arch patency in 85 
patients with critical limb ischemia. Of those, 
51% had ESRD and 78% had diabetes, showing 
that patency of both pedal arteries and pedal–
plantar arch was present in 16%, patency of one 
pedal artery in 64% and loss of patency in both 
pedal arteries in 20% of patients.15
Analysis on patency of the pedal–plantar arch and 
pedal arteries is an ongoing focus for understand-
ing poor clinical outcome after distal bypass or 
endovascular treatment. More than 20 years ago, 
it was considered that only modest success could 
be expected with pedal bypass grafts in patients 
with ESRD.14 Today, advanced endovascular 
techniques by transmetatarsal retrograde access 
of the transplantar arch can help improve clinical 
outcome in CLI.38,39 However, findings differ 
between series. Meyer and colleagues found no 
impact of quality of pedal arch on wound healing 
or survival in a cohort of 32 patients with ESRD 
after BTK angioplasty.18 Matsukaru and col-
leagues looked at perimalleolar atherosclerotic 
burden in PAD patients, 77% with diabetes and 
CKD, 60% with ESRD, that were treated with 
infrapopliteal (tibial or paramalleolar) arterial 
bypass surgery for critical limb ischemia. Those 
patients showing a higher atherosclerotic burden 
of perimalleolar arteries had a statistically 
Table 3. Association of severity of chronic kidney disease and loss of patency of pedal-plantar loop.
OR (95% CI) p value Adjusted OR*  
(95% CI)
Adjusted* 
p value
No CKD versus moderate CKD 1.43 (0.78–2.60) 0.25 0.93 (0.43–2.01) 0.85
No CKD versus severe CKD 5.42 (1.25–23.52) 0.02 8.24 (0.99–68.36) 0.05
*Adjusted models included age, sex, hypercholesterolemia, arterial hypertension and smoking.
No CKD eGFR ⩾ 60 ml/min (n = 332); moderate CKD eGFR 30–59 ml/min (n = 64); severe CKD eGFR <29 ml/min  
(n = 23).
CKD, chronic kidney disease; OR, odds ratio; CI, confidence interval; eGFR, estimated glomerular filtration rate.
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significant worse outcome for amputation-free 
survival and overall survival rate.3 Patency of both 
dorsalis pedis and plantar artery results in a higher 
wound healing rate over patients with no or single 
patent pedal artery.15 Other studies found no 
impact of pedal arch quality on amputation-free 
survival but an improved outcome in wound heal-
ing for complete or incomplete pedal arch over no 
pedal arch.16,19 None of the studies distinguished 
between DM and CKD as potentially indepen-
dently acting vascular risk factors. Results show 
an important difference between DM and CKD 
regarding the distal vascular disease pattern of 
patients with symptomatic PAD. It underlines 
that CKD, often coincident with diabetes, is a 
serious independent risk factor for pedal vascular 
disease, suggesting that patients with severe CKD 
are prone to revascularization failure and poor 
clinical outcome. If this hypothesis can be proven 
in a larger sized, adequately powered study, it 
might even be justified to define this as nephro-
pathic foot syndrome.
The main limitations of our study include its ret-
rospective design, limited generalizability due to 
sample size, and the possible selection bias that 
might contribute to results. Exclusion of patients 
with a pedal angiogram defined as unreadable for 
our analysis can be related to several factors. We 
assume that the lack of adherence to a standard-
ized protocol for high-quality angiograms is likely 
a result of the intention to save contrast media 
volume, particularly as in this case the foot lesions 
had no clinical requirement for selective pedal 
angiogram, carbon dioxide contrast medium was 
used and fretful foot movement was apparent 
(Figure 1).
The study is not powered to assess the influ-
ence of patency of the pedal–plantar arch on 
clinical outcome, but results show an important 
difference in peripheral vascular disease pattern 
that might explain the particular poor outcome 
in patients with severe CKD. Moreover, no 
direct implication to clinical relevance can be 
undertaken. Duration of diabetes and CKD 
might have had a relevant contribution to the 
disease pattern as shown. However, this infor-
mation was only available in a fragmentary form 
and a meaningful statistical computation was 
not feasible. That duration of diabetes and 
ESRD per se is an independent risk factor for 
vascular calcification is well described.33,40–42 
Methods being used were not meant to answer 
the question of influence on extent of vessel 
wall calcification. Even using a rough semi-
quantitative calcification score, the study was 
not powered to answer whether calcification 
was related to patency. Moreover, adequate 
plain films were not always available to allow 
reliable, systematic post hoc analysis. Also, there 
is no systematic information on the comedica-
tion of patients available, in particular, long-
term corticosteroid use that is associated to 
infragenicular vascular calcification, was 
unknown.43 Certain aspects on definition of the 
pedal arch have to be considered if data are 
compared with clinical outcome studies. We 
used the definition as previously described by 
Higashimori and colleagues,17 however, there is 
some variability in the literature.16,21,44
In conclusion, results indicate severe CKD as a 
vascular risk factor defining a specific subgroup of 
PAD patients at risk for pronounced below-the-
ankle artery disease. The specific atherosclerotic 
disease pattern of patients with CKD and 
‘nephropathic’ foot ischemia might have relevant 
implications with regard to contemporary endo-
vascular revascularization strategies that needs 
further evaluation.
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